

In the Claims

1-41 (canceled).

42 (currently amended). A method of treating ~~a disease~~ acute liver disease or inflammatory skin disease comprising administering to an individual having acute liver disease or inflammatory skin disease a ~~the administration of a~~ composition comprising a pharmaceutically acceptable carrier and a polypeptide, said polypeptide:

- a) consisting of SEQ ID NO: 22;
- b) comprising SEQ ID NO: 20;
- c) comprising SEQ ID NO: 27;
- d) comprising SEQ ID NO: 28;
- e) comprising SEQ ID NO: 29; or
- f) comprising SEQ ID NO: 30~~comprising SEQ ID NO: 20, 22, 27, 28, 29 or 30 to an individual having a disease, wherein the disease is an auto-immune disease, a viral liver disease, an acute liver disease, a skin disease, or an inflammatory disease.~~

43 (withdrawn). The method according to claim 42, wherein said polypeptide comprises SEQ ID NO: 20.

44 (canceled).

45 (withdrawn). The method according to claim 42, wherein said polypeptide comprises SEQ ID NO: 27.

46 (withdrawn). The method according to claim 42, wherein said polypeptide comprises SEQ ID NO: 28.

47 (withdrawn). The method according to claim 42, wherein said polypeptide comprises SEQ ID NO: 29.

48 (withdrawn). The method according to claim 42, wherein said polypeptide comprises SEQ ID NO: 30.

49 (canceled).

50 (withdrawn-new). The method according to claim 42, wherein said polypeptide consists of SEQ ID NO: 20.

51 (withdrawn-new). The method according to claim 42, wherein said polypeptide consists of SEQ ID NO: 27.

52 (withdrawn-new). The method according to claim 42, wherein said polypeptide consists of SEQ ID NO: 28.

53 (withdrawn-new). The method according to claim 42, wherein said polypeptide consists of SEQ ID NO: 29.

54 (withdrawn-new). The method according to claim 42, wherein said polypeptide consists of SEQ ID NO: 30.

55 (new). A method of decreasing TNF- $\alpha$  levels or IL-6 levels in an individual comprising the administration of a composition comprising a pharmaceutically acceptable carrier and a polypeptide, said composition being administered in an amount that reduces TNF- $\alpha$  levels or IL-6 levels in said individual and said polypeptide:

- a) comprising SEQ ID NO: 20;
- b) comprising SEQ ID NO: 27;

- c) comprising SEQ ID NO: 28;
- d) comprising SEQ ID NO: 29;
- e) comprising SEQ ID NO: 30; or
- f) comprising SEQ ID NO: 22.

56 (new). A method of decreasing TNF- $\alpha$  levels or IL-6 levels in an individual comprising the administration of a composition comprising a pharmaceutically acceptable carrier and a polypeptide, said composition being administered in an amount that reduces TNF- $\alpha$  levels or IL-6 levels in said individual and said polypeptide:

- a) consisting of SEQ ID NO: 20;
- b) consisting of SEQ ID NO: 27;
- c) consisting of SEQ ID NO: 28;
- d) consisting of SEQ ID NO: 29;
- e) consisting of SEQ ID NO: 30; or
- f) consisting of SEQ ID NO: 22.